Search Results | Showing 1 - 10 of 120 results for "Biotech" |
| | | South Korea is establishing another sovereign wealth fund, with this one to be modelled on the Future Fund. Launching the National Growth Fund yesterday, Deputy Prime Minister and Minister of Economy and Finance Yooncheol Koo said the government would ... |
| | | | ... (second) and critical infrastructure (third). They are followed by adverse outcomes of frontier technologies (quantum, biotech, geoengineering) at fourth place, and by the decline in health and wellbeing at fifth place. Compared with the G20 average ... |
| | | | ... Energy Transition Metals ETF, Lazard Global Listed Infrastructure, Milford Australian Absolute Growth Fund and Global X S&P Biotech ETF. One new option that was added to the updated termination list was the Loftus Peak Global Disruption Fund Hedged Active ... |
| | | | QIC Ventures has invested $10 million in Queensland agritech firm Nbryo, helping advance its cattle reproductive technology that can reduce seven years of breeding into a week. The seed raise, led by existing investor Tenacious Ventures alongside QIC ... |
| | | | ... adoption of artificial intelligence (AI), along with other emerging technologies such as quantum computing, robotics, biotech and genomics. "Classic economic questions are being asked about the impact of this new technology on overall productivity and ... |
| | | | ... his management and oversight of the VG1 portfolio since June 2023," Jones said. VG1's FY25 performance was marred by biotech company Opthea, which was written down to zero after unsuccessful phase three clinical trials. "This was a disappointing ... |
| | | | ... innovators could boost investment returns for everyday Australians. "Australia has shown it can punch above its weight in biotech, medtech, AI and quantum - all productivity gamechangers that could be supercharged, yet we're seeing too many of our brightest ... |
| | | | ... Finance), Gary Brown of AGL Energy (Utilities & Alternative Energy), and Joy Carolyn Linton of CSL (Healthcare, Pharma & Biotech). |
| | | | ... January end. Both said they did so recognising the potential for a positive result from another upcoming clinical trial. The biotech firm is now exploring possible options in respect of its clinical trial program "with a view to identifying whether there ... |
| | | | ... announcement. It remains suspended on the ASX and Nasdaq until March 31. Opthea last traded at 60 cents per share. The biotech firm is now exploring possible options in respect of its clinical trial program "with a view to identifying whether there is ... |
|